Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Cytokine Release Syndrome"" wg kryterium: Temat


Starter badań:

Tytuł :
COVID-19-associated cytokine storm syndrome and diagnostic principles: an old and new Issue.
Autorzy :
Yongzhi X; Department of Immunology and National Center for Biomedicine Analysis; Fifth Medical Center of Chinese PLA General Hospital, Beijing, People's Republic of China.
Pokaż więcej
Źródło :
Emerging microbes & infections [Emerg Microbes Infect] 2021 Dec; Vol. 10 (1), pp. 266-276.
Typ publikacji :
Journal Article; Review
MeSH Terms :
COVID-19/*immunology
Cytokine Release Syndrome/*diagnosis
Cytokine Release Syndrome/*immunology
Animals ; COVID-19/diagnosis ; COVID-19/genetics ; COVID-19/virology ; Cytokine Release Syndrome/genetics ; Cytokine Release Syndrome/virology ; Cytokines/genetics ; Cytokines/immunology ; Humans ; SARS-CoV-2/genetics ; SARS-CoV-2/physiology
Czasopismo naukowe
Tytuł :
Successful Treatment of Covid-19 Associated Cytokine Release Syndrome with Colchicine. A Case Report and Review of Literature.
Autorzy :
Mansouri N; Division of Pulmonary Medicine, Department of Medicine, Lausanne University Hospital (CHUV), University of Lausanne (UNIL), Lausanne, Switzerland.; Department of Clinical Immunology and Infectious Diseases, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Marjani M; The Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Tabarsi P; The Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
von Garnier C; Division of Pulmonary Medicine, Department of Medicine, Lausanne University Hospital (CHUV), University of Lausanne (UNIL), Lausanne, Switzerland.
Mansouri D; Department of Clinical Immunology and Infectious Diseases, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.; The Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.; Pediatric Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Pokaż więcej
Źródło :
Immunological investigations [Immunol Invest] 2021 Nov; Vol. 50 (8), pp. 884-890. Date of Electronic Publication: 2020 Jul 07.
Typ publikacji :
Case Reports; Journal Article; Review
MeSH Terms :
COVID-19/*drug therapy
Colchicine/*administration & dosage
Cytokine Release Syndrome/*drug therapy
Gout/*drug therapy
Administration, Oral ; Adult ; COVID-19/complications ; COVID-19/immunology ; COVID-19/virology ; Cytokine Release Syndrome/diagnosis ; Cytokine Release Syndrome/immunology ; Cytokine Release Syndrome/virology ; Gout/diagnosis ; Gout/immunology ; Gout/virology ; Humans ; Male ; SARS-CoV-2/immunology ; Treatment Outcome
SCR Protocol :
COVID-19 drug treatment
Czasopismo naukowe
Tytuł :
Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology.
Autorzy :
Song NJ; The Pelotonia Institute for Immuno-Oncology, The Ohio State University James Comprehensive Cancer Center, 460 W. 12th Ave, Columbus, OH, 43210, USA.
Allen C; The Pelotonia Institute for Immuno-Oncology, The Ohio State University James Comprehensive Cancer Center, 460 W. 12th Ave, Columbus, OH, 43210, USA.; Department of Biomedical Informatics, The Ohio State University College of Medicine, Columbus, OH, USA.
Vilgelm AE; The Pelotonia Institute for Immuno-Oncology, The Ohio State University James Comprehensive Cancer Center, 460 W. 12th Ave, Columbus, OH, 43210, USA.; Department of Pathology, The Ohio State University College of Medicine, Columbus, OH, USA.
Riesenberg BP; The Pelotonia Institute for Immuno-Oncology, The Ohio State University James Comprehensive Cancer Center, 460 W. 12th Ave, Columbus, OH, 43210, USA.
Weller KP; The Pelotonia Institute for Immuno-Oncology, The Ohio State University James Comprehensive Cancer Center, 460 W. 12th Ave, Columbus, OH, 43210, USA.
Reynolds K; The Pelotonia Institute for Immuno-Oncology, The Ohio State University James Comprehensive Cancer Center, 460 W. 12th Ave, Columbus, OH, 43210, USA.
Chakravarthy KB; The Pelotonia Institute for Immuno-Oncology, The Ohio State University James Comprehensive Cancer Center, 460 W. 12th Ave, Columbus, OH, 43210, USA.; The Ohio State University College of Medicine, Columbus, OH, USA.
Kumar A; Department of Pathology, The Ohio State University College of Medicine, Columbus, OH, USA.; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Khatiwada A; Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA.
Sun Z; Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA.
Ma A; The Pelotonia Institute for Immuno-Oncology, The Ohio State University James Comprehensive Cancer Center, 460 W. 12th Ave, Columbus, OH, 43210, USA.; Department of Biomedical Informatics, The Ohio State University College of Medicine, Columbus, OH, USA.
Chang Y; The Pelotonia Institute for Immuno-Oncology, The Ohio State University James Comprehensive Cancer Center, 460 W. 12th Ave, Columbus, OH, 43210, USA.; Department of Biomedical Informatics, The Ohio State University College of Medicine, Columbus, OH, USA.
Yusuf M; The Pelotonia Institute for Immuno-Oncology, The Ohio State University James Comprehensive Cancer Center, 460 W. 12th Ave, Columbus, OH, 43210, USA.
Li A; The Pelotonia Institute for Immuno-Oncology, The Ohio State University James Comprehensive Cancer Center, 460 W. 12th Ave, Columbus, OH, 43210, USA.; The Ohio State University College of Medicine, Columbus, OH, USA.
Zeng C; Center for Retrovirus Research and Department of Veterinary Biosciences, The Ohio State University, Columbus, OH, USA.
Evans JP; Center for Retrovirus Research and Department of Veterinary Biosciences, The Ohio State University, Columbus, OH, USA.
Bucci D; The Pelotonia Institute for Immuno-Oncology, The Ohio State University James Comprehensive Cancer Center, 460 W. 12th Ave, Columbus, OH, 43210, USA.
Gunasena M; Department of Microbial Infection and Immunity, The Ohio State University College of Medicine, Columbus, OH, USA.; Department of Veterinary Biosciences, The Ohio State University College of Veterinary Medicine, Columbus, OH, USA.
Xu M; Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, OH, USA.
Liyanage NPM; Department of Microbial Infection and Immunity, The Ohio State University College of Medicine, Columbus, OH, USA.; Department of Veterinary Biosciences, The Ohio State University College of Veterinary Medicine, Columbus, OH, USA.
Bolyard C; The Pelotonia Institute for Immuno-Oncology, The Ohio State University James Comprehensive Cancer Center, 460 W. 12th Ave, Columbus, OH, 43210, USA.
Velegraki M; The Pelotonia Institute for Immuno-Oncology, The Ohio State University James Comprehensive Cancer Center, 460 W. 12th Ave, Columbus, OH, 43210, USA.
Liu SL; Center for Retrovirus Research and Department of Veterinary Biosciences, The Ohio State University, Columbus, OH, USA.
Ma Q; The Pelotonia Institute for Immuno-Oncology, The Ohio State University James Comprehensive Cancer Center, 460 W. 12th Ave, Columbus, OH, 43210, USA.; Department of Biomedical Informatics, The Ohio State University College of Medicine, Columbus, OH, USA.
Devenport M; OncoC4, Rockville, MD, USA.
Liu Y; OncoC4, Rockville, MD, USA.
Zheng P; OncoC4, Rockville, MD, USA.
Malvestutto CD; Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, OH, USA.
Chung D; The Pelotonia Institute for Immuno-Oncology, The Ohio State University James Comprehensive Cancer Center, 460 W. 12th Ave, Columbus, OH, 43210, USA.; Department of Biomedical Informatics, The Ohio State University College of Medicine, Columbus, OH, USA.
Li Z; The Pelotonia Institute for Immuno-Oncology, The Ohio State University James Comprehensive Cancer Center, 460 W. 12th Ave, Columbus, OH, 43210, USA. .; Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, OH, USA. .
Pokaż więcej
Źródło :
Journal of hematology & oncology [J Hematol Oncol] 2022 Jan 10; Vol. 15 (1), pp. 5. Date of Electronic Publication: 2022 Jan 10.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
MeSH Terms :
CD24 Antigen/*therapeutic use
COVID-19/*prevention & control
Cytokine Release Syndrome/*prevention & control
Inflammation/*prevention & control
SARS-CoV-2/*drug effects
Aged ; Alarmins/immunology ; Alarmins/metabolism ; CD24 Antigen/chemistry ; COVID-19/immunology ; COVID-19/virology ; Cytokine Release Syndrome/immunology ; Cytokine Release Syndrome/metabolism ; Double-Blind Method ; Female ; HMGB1 Protein/immunology ; HMGB1 Protein/metabolism ; Heat-Shock Proteins/immunology ; Heat-Shock Proteins/metabolism ; Homeostasis/drug effects ; Homeostasis/immunology ; Humans ; Inflammation/immunology ; Inflammation/metabolism ; Killer Cells, Natural/immunology ; Killer Cells, Natural/metabolism ; Killer Cells, Natural/virology ; Male ; Middle Aged ; SARS-CoV-2/immunology ; SARS-CoV-2/physiology ; Solubility ; T-Lymphocytes/immunology ; T-Lymphocytes/metabolism ; T-Lymphocytes/virology ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Beneficial effects of novel aureobasidium pullulans strains produced beta-1,3-1,6 glucans on interleukin-6 and D-dimer levels in COVID-19 patients; results of a randomized multiple-arm pilot clinical study.
Autorzy :
Raghavan K; Dept of Paediatric Neurology, Kenmax Healthcare Services Pvt Ltd, Madurai, India; Research & Development Division, Sarvee Integra Pvt Ltd, Chennai, India; Mary-Yoshio Translational Hexagon (MYTH), Nichi-In Centre for Regenerative Medicine (NCRM), Chennai, India. Electronic address: .
Dedeepiya VD; Mary-Yoshio Translational Hexagon (MYTH), Nichi-In Centre for Regenerative Medicine (NCRM), Chennai, India. Electronic address: .
Suryaprakash V; Department of Urology, Yashoda Hospitals, Hyderabad, India. Electronic address: .
Rao KS; Instituto de Investigaciones Científicas y Servicios de Alta Tecnología (INDICASAT AIP), City of Knowledge, Panama. Electronic address: .
Ikewaki N; Dept. of Medical Life Science, Kyushu University of Health and Welfare, Japan; Institute of Immunology, Junsei Educational Institute, Nobeoka, Miyazaki, Japan. Electronic address: .
Sonoda T; Institute of Immunology, Junsei Educational Institute, Nobeoka, Miyazaki, Japan. Electronic address: .
Levy GA; Professor Emeritus, Medicine and Immunology, University of Toronto, Ontario, Canada. Electronic address: .
Iwasaki M; Centre for Advancing Clinical Research (CACR), University of Yamanashi - School of Medicine, Chuo, Japan. Electronic address: .
Senthilkumar R; Fujio-Eiji Academic Terrain (FEAT), Nichi-In Centre for Regenerative Medicine (NCRM), Chennai, India. Electronic address: .
Preethy S; Fujio-Eiji Academic Terrain (FEAT), Nichi-In Centre for Regenerative Medicine (NCRM), Chennai, India. Electronic address: .
Abraham SJ; Mary-Yoshio Translational Hexagon (MYTH), Nichi-In Centre for Regenerative Medicine (NCRM), Chennai, India; Centre for Advancing Clinical Research (CACR), University of Yamanashi - School of Medicine, Chuo, Japan; Antony, Xavier Interdisciplinary Scholastics (AXIS), GN Corporation Co. Ltd., Kofu, Japan. Electronic address: .
Pokaż więcej
Źródło :
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2022 Jan; Vol. 145, pp. 112243. Date of Electronic Publication: 2021 Sep 25.
Typ publikacji :
Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms :
Aureobasidium*
COVID-19*/blood
COVID-19*/diagnosis
COVID-19*/drug therapy
Cytokine Release Syndrome*/blood
Cytokine Release Syndrome*/etiology
Cytokine Release Syndrome*/prevention & control
Fibrin Fibrinogen Degradation Products/*analysis
Interleukin-6/*analysis
beta-Glucans/*administration & dosage
Biomarkers/blood ; Complementary Therapies/methods ; Dietary Supplements ; Female ; Humans ; Immunologic Factors/administration & dosage ; Male ; Middle Aged ; Pilot Projects ; SARS-CoV-2 ; Treatment Outcome
SCR Organism :
Aureobasidium pullulans
Czasopismo naukowe
Tytuł :
Exhausted NK cells and cytokine storms in COVID-19: Whether NK cell therapy could be a therapeutic choice.
Autorzy :
Ghasemzadeh M; Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran.
Ghasemzadeh A; Iran University of Medical Science, Tehran, Iran.
Hosseini E; Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran; Department of Immunology, Alfred Medical Research and Education Precinct, Monash University, Melbourne, Victoria, Australia; Australian Centre for Blood Diseases, Monash University, Melbourne, Victoria, Australia. Electronic address: .
Pokaż więcej
Źródło :
Human immunology [Hum Immunol] 2022 Jan; Vol. 83 (1), pp. 86-98. Date of Electronic Publication: 2021 Sep 08.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Adoptive Transfer*/adverse effects
COVID-19/*therapy
Cytokine Release Syndrome/*therapy
Cytokines/*immunology
Killer Cells, Natural/*transplantation
SARS-CoV-2/*immunology
Animals ; COVID-19/immunology ; COVID-19/metabolism ; COVID-19/virology ; Cytokine Release Syndrome/immunology ; Cytokine Release Syndrome/metabolism ; Cytokine Release Syndrome/virology ; Cytokines/metabolism ; Cytotoxicity, Immunologic ; Host-Pathogen Interactions ; Humans ; Immunologic Memory ; Killer Cells, Natural/immunology ; Killer Cells, Natural/metabolism ; Killer Cells, Natural/virology ; SARS-CoV-2/pathogenicity ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells.
Autorzy :
Lichtenstein DA; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Schischlik F; Cancer Data Science Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Shao L; Center for Cellular Engineering, Department of Transfusion Medicine, NIH Clinical Center, Bethesda, MD.
Steinberg SM; Biostatistics and Data Management Section, Center for Cancer Research, Bethesda, MD.
Yates B; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Wang HW; Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Wang Y; Applied Developmental Research Directorate, Leidos Biomedical Research, Inc, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD.
Inglefield J; Applied Developmental Research Directorate, Leidos Biomedical Research, Inc, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD.
Dulau-Florea A; Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Ceppi F; Department of Pediatrics, Seattle Children's Hospital, Seattle, WA.; Paediatric Haematology-Oncology Unit, Division of Paediatrics, Department Woman-Mother-Child, University Hospital of Lausanne, Lausanne, Switzerland.
Hermida LC; Cancer Data Science Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, MD.; Center for Bioinformatics and Computational Biology, University of Maryland, College Park, MD.
Stringaris K; Transplantation Immunology, National Heart, Lung and Blood Institute, Bethesda, MD.
Dunham K; Applied Developmental Research Directorate, Leidos Biomedical Research, Inc, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD.
Homan P; Center for Cancer Research Collaborative Bioinformatics Resource, National Cancer Institute, National Institutes of Health, Bethesda, MD.; Advanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research, Fredrick, MD.
Jailwala P; Center for Cancer Research Collaborative Bioinformatics Resource, National Cancer Institute, National Institutes of Health, Bethesda, MD.; Advanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research, Fredrick, MD.
Mirazee J; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Robinson W; Cancer Data Science Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, MD.; Paediatric Haematology-Oncology Unit, Division of Paediatrics, Department Woman-Mother-Child, University Hospital of Lausanne, Lausanne, Switzerland.
Chisholm KM; Department of Laboratories, Seattle Children's Hospital, Seattle, WA.
Yuan C; Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Stetler-Stevenson M; Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Ombrello AK; Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD; and.
Jin J; Center for Cellular Engineering, Department of Transfusion Medicine, NIH Clinical Center, Bethesda, MD.
Fry TJ; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.; University of Colorado Anschutz Medical Campus and Center for Cancer and Blood Disorders, Children's Hospital of Colorado, Aurora, CO.
Taylor N; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Highfill SL; Center for Cellular Engineering, Department of Transfusion Medicine, NIH Clinical Center, Bethesda, MD.
Jin P; Center for Cellular Engineering, Department of Transfusion Medicine, NIH Clinical Center, Bethesda, MD.
Gardner RA; Applied Developmental Research Directorate, Leidos Biomedical Research, Inc, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD.
Shalabi H; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Ruppin E; Cancer Data Science Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Stroncek DF; Center for Cellular Engineering, Department of Transfusion Medicine, NIH Clinical Center, Bethesda, MD.
Shah NN; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Pokaż więcej
Źródło :
Blood [Blood] 2021 Dec 16; Vol. 138 (24), pp. 2469-2484.
Typ publikacji :
Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Cytokine Release Syndrome/*etiology
Immunotherapy, Adoptive/*adverse effects
Lymphohistiocytosis, Hemophagocytic/*etiology
Sialic Acid Binding Ig-like Lectin 2/*immunology
Adult ; CD8-Positive T-Lymphocytes/immunology ; Cytokine Release Syndrome/diagnosis ; Cytokine Release Syndrome/immunology ; Female ; Humans ; Immunotherapy, Adoptive/methods ; Killer Cells, Natural/immunology ; Lymphohistiocytosis, Hemophagocytic/diagnosis ; Lymphohistiocytosis, Hemophagocytic/immunology ; Male ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Endothelial dysfunction contributes to severe COVID-19 in combination with dysregulated lymphocyte responses and cytokine networks.
Autorzy :
Ruhl L; Institute of Transplant Immunology, MHH, D, Hanover, Germany.
Pink I; Department of Pneumology, MHH, D, Hanover, Germany.
Kühne JF; Institute of Transplant Immunology, MHH, D, Hanover, Germany.
Beushausen K; Institute of Transplant Immunology, MHH, D, Hanover, Germany.
Keil J; Institute of Transplant Immunology, MHH, D, Hanover, Germany.
Christoph S; Institute of Transplant Immunology, MHH, D, Hanover, Germany.
Sauer A; Department of Pneumology, MHH, D, Hanover, Germany.
Boblitz L; Department of Pneumology, MHH, D, Hanover, Germany.
Schmidt J; Department of Pneumology, MHH, D, Hanover, Germany.
David S; Department of Intensive Care Medicine, University of Zurich, CH, Zurich, Switzerland.
Jäck HM; Division of Molecular Immunology, Internal Medicine III, Nikolaus-Fiebiger-Center of Molecular Medicine, Friedrich-Alexander University Erlangen-Nürnberg, D, Erlangen, Germany.
Roth E; Division of Molecular Immunology, Internal Medicine III, Nikolaus-Fiebiger-Center of Molecular Medicine, Friedrich-Alexander University Erlangen-Nürnberg, D, Erlangen, Germany.
Cornberg M; Department of Gastroenterology Hepatology and Endocrinology, MHH, D, Hanover, Germany.; Center for Individualized Infection Medicine CiiM, Hanover, Germany.
Schulz TF; Institute of Virology, MHH, D, Hanover, Germany.; German Center for Infection Research, DZIF, TTU-IICH, Marburg, Germany.; Excellence Cluster 2155 RESIST, MHH, Hanover, Germany.
Welte T; Department of Pneumology, MHH, D, Hanover, Germany.; German Center for Lung Diseases DZL/BREATH, Marburg, Germany.
Höper MM; Department of Pneumology, MHH, D, Hanover, Germany.; German Center for Lung Diseases DZL/BREATH, Marburg, Germany.
Falk CS; Institute of Transplant Immunology, MHH, D, Hanover, Germany. .; German Center for Infection Research, DZIF, TTU-IICH, Marburg, Germany. .; German Center for Lung Diseases DZL/BREATH, Marburg, Germany. .
Pokaż więcej
Źródło :
Signal transduction and targeted therapy [Signal Transduct Target Ther] 2021 Dec 10; Vol. 6 (1), pp. 418. Date of Electronic Publication: 2021 Dec 10.
Typ publikacji :
Journal Article; Observational Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Viral/*blood
Blood Proteins/*metabolism
COVID-19/*diagnosis
Cytokine Release Syndrome/*diagnosis
Endothelium, Vascular/*virology
Lymphopenia/*diagnosis
SARS-CoV-2/*pathogenicity
Biomarkers/blood ; C-Reactive Protein/metabolism ; COVID-19/immunology ; COVID-19/mortality ; COVID-19/virology ; Chemokine CXCL10/blood ; Chemokine CXCL9/blood ; Cluster Analysis ; Convalescence ; Cytokine Release Syndrome/immunology ; Cytokine Release Syndrome/mortality ; Cytokine Release Syndrome/virology ; Disease Progression ; Endothelium, Vascular/immunology ; Granulocytes/immunology ; Granulocytes/virology ; Hematopoietic Cell Growth Factors/blood ; Hepatocyte Growth Factor/blood ; Humans ; Intensive Care Units ; Interleukin-12 Subunit p40/blood ; Interleukin-6/blood ; Interleukin-8/blood ; Killer Cells, Natural/immunology ; Killer Cells, Natural/virology ; Lectins, C-Type/blood ; Lymphopenia/immunology ; Lymphopenia/mortality ; Lymphopenia/virology ; Plasma Cells/immunology ; Plasma Cells/virology ; Survival Analysis ; T-Lymphocytes/immunology ; T-Lymphocytes/virology
Czasopismo naukowe
Tytuł :
Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline.
Autorzy :
Santomasso BD; Memorial Sloan Kettering Cancer Center, New York, NY.
Nastoupil LJ; MD Anderson Cancer Center, Houston, TX.
Adkins S; MD Anderson Cancer Center, Houston, TX.
Lacchetti C; American Society of Clinical Oncology, Alexandria, VA.
Schneider BJ; University of Michigan Health System, Ann Arbor, MI.
Anadkat M; Washington University, St Louis, MO.
Atkins MB; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC.
Brassil KJ; MD Anderson Cancer Center, Houston, TX.
Caterino JM; The Ohio State University Wexner Medical Center, Columbus, OH.
Chau I; Royal Marsden Hospital and Institute of Cancer Research, London and Surrey, United Kingdom.
Davies MJ; Smilow Cancer Hospital and Yale School of Nursing, New Haven, CT.
Ernstoff MS; National Cancer Institute, Bethesda, MD.
Fecher L; University of Michigan Health System, Ann Arbor, MI.
Funchain P; Cleveland Clinic, Cleveland, OH.
Jaiyesimi I; Cancer Care Associates PC, Royal Oak, MI.
Mammen JS; Johns Hopkins University, Baltimore, MD.
Naidoo J; Beaumont Hospital, Dublin, Ireland and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD.
Naing A; MD Anderson Cancer Center, Houston, TX.
Phillips T; City of Hope, Duarte, CA.
Porter LD; Patient Advocate, Colon Cancer Alliance, Washington, DC.
Reichner CA; Georgetown University, Washington, DC.
Seigel C; Patient Advocate, MGH Cancer Center, Boston, MA.
Song JM; Cleveland Clinic, Cleveland, OH.
Spira A; Virginia Cancer Specialists and US Oncology, Fairfax, VA.
Suarez-Almazor M; MD Anderson Cancer Center, Houston, TX.
Swami U; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.
Thompson JA; Seattle Cancer Care Alliance, University of Washington/Fred Hutchinson, Seattle, WA.
Vikas P; University of Iowa, Iowa City, IA.
Wang Y; MD Anderson Cancer Center, Houston, TX.
Weber JS; NYU Langone Medical Center, New York, NY.
Bollin K; Scripps MD Anderson Cancer Center, San Diego, CA.
Ghosh M; University of Michigan, Ann Arbor, MI.
Pokaż więcej
Źródło :
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2021 Dec 10; Vol. 39 (35), pp. 3978-3992. Date of Electronic Publication: 2021 Nov 01.
Typ publikacji :
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms :
Cytokine Release Syndrome/*therapy
Drug-Related Side Effects and Adverse Reactions/*therapy
Immunotherapy, Adoptive/*adverse effects
Neoplasms/*therapy
Practice Guidelines as Topic/*standards
Cytokine Release Syndrome/etiology ; Cytokine Release Syndrome/pathology ; Disease Management ; Drug-Related Side Effects and Adverse Reactions/etiology ; Drug-Related Side Effects and Adverse Reactions/pathology ; Humans ; Neoplasms/immunology ; Neoplasms/pathology ; Prognosis
Czasopismo naukowe
Tytuł :
Purinergic receptor ligands: the cytokine storm attenuators, potential therapeutic agents for the treatment of COVID-19.
Autorzy :
Zarei M; Department of Pharmacology, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Sahebi Vaighan N; Department of Pharmacology, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Ziai SA; Department of Pharmacology, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Pokaż więcej
Źródło :
Immunopharmacology and immunotoxicology [Immunopharmacol Immunotoxicol] 2021 Dec; Vol. 43 (6), pp. 633-643. Date of Electronic Publication: 2021 Oct 14.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Anti-Inflammatory Agents/*therapeutic use
COVID-19/*drug therapy
Cytokine Release Syndrome/*prevention & control
Cytokines/*blood
Purinergic Antagonists/*therapeutic use
Receptors, Purinergic/*drug effects
SARS-CoV-2/*drug effects
Animals ; Anti-Inflammatory Agents/adverse effects ; Biomarkers/blood ; COVID-19/blood ; COVID-19/immunology ; COVID-19/virology ; Cytokine Release Syndrome/blood ; Cytokine Release Syndrome/immunology ; Cytokine Release Syndrome/virology ; Host-Pathogen Interactions ; Humans ; Ligands ; Molecular Targeted Therapy ; Multiple Organ Failure/immunology ; Multiple Organ Failure/prevention & control ; Multiple Organ Failure/virology ; Purinergic Antagonists/adverse effects ; Receptors, Purinergic/metabolism ; SARS-CoV-2/immunology ; SARS-CoV-2/pathogenicity ; Signal Transduction
SCR Protocol :
COVID-19 drug treatment
Czasopismo naukowe
Tytuł :
Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial.
Autorzy :
Declercq J; Laboratory of Mucosal Immunology, VIB-UGhent Center for Inflammation Research, Ghent University, Ghent, Belgium; Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium; Department of Pulmonary Medicine, University Hospital Ghent, Ghent, Belgium.
Van Damme KFA; Laboratory of Mucosal Immunology, VIB-UGhent Center for Inflammation Research, Ghent University, Ghent, Belgium; Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium; Department of Pulmonary Medicine, University Hospital Ghent, Ghent, Belgium.
De Leeuw E; Laboratory of Mucosal Immunology, VIB-UGhent Center for Inflammation Research, Ghent University, Ghent, Belgium; Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium; Department of Pulmonary Medicine, University Hospital Ghent, Ghent, Belgium.
Maes B; Laboratory of Mucosal Immunology, VIB-UGhent Center for Inflammation Research, Ghent University, Ghent, Belgium; Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium; Department of Pulmonary Medicine, University Hospital Ghent, Ghent, Belgium.
Bosteels C; Laboratory of Mucosal Immunology, VIB-UGhent Center for Inflammation Research, Ghent University, Ghent, Belgium; Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium; Department of Pulmonary Medicine, University Hospital Ghent, Ghent, Belgium.
Tavernier SJ; Laboratory of Mucosal Immunology, VIB-UGhent Center for Inflammation Research, Ghent University, Ghent, Belgium; Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium; Primary Immunodeficiency Research Laboratory, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.
De Buyser S; Biostatistics Unit, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.
Colman R; Biostatistics Unit, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.
Hites M; Clinic of Infectious Diseases, Cliniques Universitaires de Bruxelles, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.
Verschelden G; Clinic of Infectious Diseases, Cliniques Universitaires de Bruxelles, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.
Fivez T; Intensive Care Unit, ZOL Genk General Hospital, Genk, Belgium.
Moerman F; Department of Infectious Diseases, CHR de La Citadelle General Hospital, Liège, Belgium.
Demedts IK; Department of Pulmonary Medicine, AZ Delta General Hospital, Roeselare, Belgium.
Dauby N; Institute for Medical Immunology, Université Libre de Bruxelles and CHU Saint-Pierre University Hospital, Brussels, Belgium.
De Schryver N; Intensive Care Unit, Clinique Saint-Pierre, Ottignies, Belgium.
Govaerts E; Department of Pulmonary Medicine, AZ Sint-Lucas General Hospital, Ghent, Belgium.
Vandecasteele SJ; Department of Infectious Diseases, AZ Sint-Jan Brugge-Oostende, Brugge, Belgium.
Van Laethem J; Department of Internal Medicine, Universitair Ziekenhuis Brussel, Brussels, Belgium.
Anguille S; Department of Hematology, University Hospital Antwerp, Antwerp, Belgium.
van der Hilst J; Department of Infectious Diseases and Immune Pathology, Jessa General Hospital and Limburg Clinical Research Center, Hasselt University, Hasselt, Belgium.
Misset B; Department of Intensive Care Medicine, University Hospital, Liège, Belgium.
Slabbynck H; Department of Pulmonary Medicine, ZNA General Hospital, Antwerp, Belgium.
Wittebole X; Intensive Care Unit, Saint Luc University Hospital, UC Louvain, Brussels, Belgium.
Liénart F; Department of Internal Medicine, CHU Tivoli University Hospital, La Louvière, Belgium.
Legrand C; Institute of Statistics, Biostatistics and Actuarial Sciences (ISBA), Louvain Institute for Data Analysis and Modeling, Louvain-la-Neuve, Belgium.
Buyse M; (22)IDDI, Louvain-la-Neuve, and Interuniversity Institute for Biostatistics and Statistical Bioinformatics, Hasselt, Belgium.
Stevens D; Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium; Department of Pulmonary Medicine, University Hospital Ghent, Ghent, Belgium.
Bauters F; Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium; Department of Pulmonary Medicine, University Hospital Ghent, Ghent, Belgium.
Seys LJM; Laboratory of Mucosal Immunology, VIB-UGhent Center for Inflammation Research, Ghent University, Ghent, Belgium; Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.
Aegerter H; Laboratory of Mucosal Immunology, VIB-UGhent Center for Inflammation Research, Ghent University, Ghent, Belgium; Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.
Smole U; Laboratory of Mucosal Immunology, VIB-UGhent Center for Inflammation Research, Ghent University, Ghent, Belgium; Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.
Bosteels V; Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium; Laboratory of ER Stress and Inflammation, VIB-UGhent Center for Inflammation Research, Ghent University, Ghent, Belgium.
Hoste L; Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium; Primary Immunodeficiency Research Laboratory, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.
Naesens L; Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium; Primary Immunodeficiency Research Laboratory, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.
Haerynck F; Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium; Primary Immunodeficiency Research Laboratory, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.
Vandekerckhove L; Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium; Department of Infectious Diseases, University Hospital Ghent, Ghent, Belgium.
Depuydt P; Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium; Intensive Care Unit, University Hospital Ghent, Ghent, Belgium.
van Braeckel E; Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium; Department of Pulmonary Medicine, University Hospital Ghent, Ghent, Belgium.
Rottey S; Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium; Drug Research Unit, Ghent University, Ghent, Belgium.
Peene I; Department of Rheumatology, AZ Sint-Jan Brugge-Oostende, Brugge, Belgium.
Van Der Straeten C; Health Innovation Research, University Hospital Ghent, Ghent, Belgium.
Hulstaert F; Belgian Health Care Knowledge Centre, Brussels, Belgium.
Lambrecht BN; Laboratory of Mucosal Immunology, VIB-UGhent Center for Inflammation Research, Ghent University, Ghent, Belgium; Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium; Department of Pulmonary Medicine, University Hospital Ghent, Ghent, Belgium. Electronic address: .
Pokaż więcej
Źródło :
The Lancet. Respiratory medicine [Lancet Respir Med] 2021 Dec; Vol. 9 (12), pp. 1427-1438. Date of Electronic Publication: 2021 Oct 29.
Typ publikacji :
Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
COVID-19*/drug therapy
Cytokine Release Syndrome*/drug therapy
Cytokine Release Syndrome*/virology
Respiratory Insufficiency*/drug therapy
Respiratory Insufficiency*/virology
Antibodies, Monoclonal/*therapeutic use
Antibodies, Monoclonal, Humanized/*therapeutic use
Aged ; Belgium ; Female ; Ferritins ; Humans ; Hypoxia ; Interleukin-1/antagonists & inhibitors ; Interleukin-6/antagonists & inhibitors ; Male ; Middle Aged ; Oxygen ; Prospective Studies ; SARS-CoV-2 ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Community-acquired methicillin-resistant Staphylococcus aureus provoked cytokine storm causing severe infection on BALB/c mice.
Autorzy :
Liao F; Department of Respiratory Medicine, The First People's Hospital of Yunnan Province, 650022, Kunming, PR China; Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, 650500, PR China; The Affiliated Hospital of Kunming University of Science and Technology, Kunming, 650500, PR China.
Gu W; Department of Acute Infectious Diseases Control and Prevention, Yunnan Provincial Centre for Disease Control and Prevention, 650022, Kunming, PR China.
Fu X; Department of Acute Infectious Diseases Control and Prevention, Yunnan Provincial Centre for Disease Control and Prevention, 650022, Kunming, PR China.
Yuan B; The Affiliated Hospital of Kunming University of Science and Technology, Kunming, 650500, PR China.
Zhang Y; Department of Respiratory Medicine, The First People's Hospital of Yunnan Province, 650022, Kunming, PR China; The Affiliated Hospital of Kunming University of Science and Technology, Kunming, 650500, PR China. Electronic address: .
Pokaż więcej
Źródło :
Molecular immunology [Mol Immunol] 2021 Dec; Vol. 140, pp. 167-174. Date of Electronic Publication: 2021 Oct 28.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Community-Acquired Infections/*microbiology
Cytokine Release Syndrome/*microbiology
Methicillin-Resistant Staphylococcus aureus/*physiology
Staphylococcal Infections/*microbiology
Animals ; Community-Acquired Infections/genetics ; Cytokine Release Syndrome/genetics ; Cytokine Release Syndrome/pathology ; Disease Models, Animal ; Interleukin-6/metabolism ; Kaplan-Meier Estimate ; Methicillin-Resistant Staphylococcus aureus/isolation & purification ; Mice, Inbred BALB C ; Organ Specificity ; Staphylococcal Infections/genetics ; Staphylococcal Infections/pathology ; Transcriptome/genetics
Czasopismo naukowe
Tytuł :
Effects of β-Blockers on the Sympathetic and Cytokines Storms in Covid-19.
Autorzy :
Al-Kuraishy HM; Department of Clinical Pharmacology and Medicine, College of Medicine, ALmustansiriyia University, Baghdad, Iraq.
Al-Gareeb AI; Department of Clinical Pharmacology and Medicine, College of Medicine, ALmustansiriyia University, Baghdad, Iraq.
Mostafa-Hedeab G; Pharmacology Department, Health Sciences Research Unit, Medical College, Jouf University, Sakaka, Saudi Arabia.
Kasozi KI; Infection Medicine, Deanery of Biomedical Sciences, College of Medicine and Veterinary Medicine, The University of Edinburgh, Edinburgh, United Kingdom.; School of Medicine, Kabale Unviersity, Kabale, Uganda.
Zirintunda G; Department of Animal Production and Management, Faculty of Agriculture and Animal Sciences, Busitema University, Tororo, Uganda.
Aslam A; Laboratory Medicine, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Saudi Arabia.
Allahyani M; Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif, Saudi Arabia.
Welburn SC; Infection Medicine, Deanery of Biomedical Sciences, College of Medicine and Veterinary Medicine, The University of Edinburgh, Edinburgh, United Kingdom.; Zhejiang University-University of Edinburgh Institute, Zhejiang University School of Medicine, Zhejiang University, Haining, China.
Batiha GE; Department of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour, Egypt.
Pokaż więcej
Źródło :
Frontiers in immunology [Front Immunol] 2021 Nov 11; Vol. 12, pp. 749291. Date of Electronic Publication: 2021 Nov 11 (Print Publication: 2021).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Adrenergic beta-Antagonists/*therapeutic use
COVID-19/*drug therapy
Cytokine Release Syndrome/*drug therapy
Sympathetic Nervous System/*drug effects
Anti-Inflammatory Agents/therapeutic use ; COVID-19/complications ; COVID-19/metabolism ; COVID-19/physiopathology ; Catecholamines/metabolism ; Cytokine Release Syndrome/etiology ; Cytokine Release Syndrome/metabolism ; Cytokine Release Syndrome/physiopathology ; Cytokines/metabolism ; Humans ; Neuroinflammatory Diseases/drug therapy ; Neuroinflammatory Diseases/etiology ; Neuroinflammatory Diseases/metabolism ; Neuroinflammatory Diseases/physiopathology ; SARS-CoV-2/pathogenicity ; Sympathetic Nervous System/metabolism ; Sympathetic Nervous System/physiopathology
SCR Protocol :
COVID-19 drug treatment
Czasopismo naukowe
Tytuł :
Mycobacterium tuberculosis effector PPE36 attenuates host cytokine storm damage via inhibiting macrophage M1 polarization.
Autorzy :
Gong Z; State Key Laboratory Breeding Base of Eco-Environment and Bio-Resource of the Three Gorges Area, Key Laboratory of Eco-environments in Three Gorges Reservoir Region, Ministry of Education, School of Life Sciences, Institute of Modern Biopharmaceuticals, Southwest University, Chongqing, China.
Han S; State Key Laboratory Breeding Base of Eco-Environment and Bio-Resource of the Three Gorges Area, Key Laboratory of Eco-environments in Three Gorges Reservoir Region, Ministry of Education, School of Life Sciences, Institute of Modern Biopharmaceuticals, Southwest University, Chongqing, China.
Liang T; State Key Laboratory Breeding Base of Eco-Environment and Bio-Resource of the Three Gorges Area, Key Laboratory of Eco-environments in Three Gorges Reservoir Region, Ministry of Education, School of Life Sciences, Institute of Modern Biopharmaceuticals, Southwest University, Chongqing, China.
Zhang H; State Key Laboratory Breeding Base of Eco-Environment and Bio-Resource of the Three Gorges Area, Key Laboratory of Eco-environments in Three Gorges Reservoir Region, Ministry of Education, School of Life Sciences, Institute of Modern Biopharmaceuticals, Southwest University, Chongqing, China.
Sun Q; State Key Laboratory Breeding Base of Eco-Environment and Bio-Resource of the Three Gorges Area, Key Laboratory of Eco-environments in Three Gorges Reservoir Region, Ministry of Education, School of Life Sciences, Institute of Modern Biopharmaceuticals, Southwest University, Chongqing, China.
Pan H; State Key Laboratory Breeding Base of Eco-Environment and Bio-Resource of the Three Gorges Area, Key Laboratory of Eco-environments in Three Gorges Reservoir Region, Ministry of Education, School of Life Sciences, Institute of Modern Biopharmaceuticals, Southwest University, Chongqing, China.
Wang H; State Key Laboratory Breeding Base of Eco-Environment and Bio-Resource of the Three Gorges Area, Key Laboratory of Eco-environments in Three Gorges Reservoir Region, Ministry of Education, School of Life Sciences, Institute of Modern Biopharmaceuticals, Southwest University, Chongqing, China.
Yang J; State Key Laboratory Breeding Base of Eco-Environment and Bio-Resource of the Three Gorges Area, Key Laboratory of Eco-environments in Three Gorges Reservoir Region, Ministry of Education, School of Life Sciences, Institute of Modern Biopharmaceuticals, Southwest University, Chongqing, China.
Cheng L; Key Laboratory of Luminescent and Real-Time Analytical Chemistry (Southwest University), Ministry of Education, College of Pharmaceutical Sciences, Southwest University, Chongqing, China.
Lv X; State Key Laboratory Breeding Base of Eco-Environment and Bio-Resource of the Three Gorges Area, Key Laboratory of Eco-environments in Three Gorges Reservoir Region, Ministry of Education, School of Life Sciences, Institute of Modern Biopharmaceuticals, Southwest University, Chongqing, China.
Yue Q; State Key Laboratory Breeding Base of Eco-Environment and Bio-Resource of the Three Gorges Area, Key Laboratory of Eco-environments in Three Gorges Reservoir Region, Ministry of Education, School of Life Sciences, Institute of Modern Biopharmaceuticals, Southwest University, Chongqing, China.
Fan L; Shanghai Clinic and Research Center of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai Key Laboratory of Tuberculosis, Shanghai, China.
Xie J; State Key Laboratory Breeding Base of Eco-Environment and Bio-Resource of the Three Gorges Area, Key Laboratory of Eco-environments in Three Gorges Reservoir Region, Ministry of Education, School of Life Sciences, Institute of Modern Biopharmaceuticals, Southwest University, Chongqing, China.
Pokaż więcej
Źródło :
Journal of cellular physiology [J Cell Physiol] 2021 Nov; Vol. 236 (11), pp. 7405-7420. Date of Electronic Publication: 2021 May 07.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antigens, Bacterial/*metabolism
Bacterial Proteins/*metabolism
Cytokine Release Syndrome/*prevention & control
Cytokines/*metabolism
Inflammation Mediators/*metabolism
Macrophages/*microbiology
Mycobacterium Infections, Nontuberculous/*microbiology
Mycobacterium smegmatis/*metabolism
Animals ; Antigens, Bacterial/genetics ; Antigens, Bacterial/immunology ; Bacterial Proteins/genetics ; Bacterial Proteins/immunology ; Cytokine Release Syndrome/immunology ; Cytokine Release Syndrome/metabolism ; Cytokine Release Syndrome/microbiology ; Disease Models, Animal ; Extracellular Signal-Regulated MAP Kinases/metabolism ; Female ; Host-Pathogen Interactions ; Humans ; Macrophages/immunology ; Macrophages/metabolism ; Mice, Inbred C57BL ; Mycobacterium Infections, Nontuberculous/immunology ; Mycobacterium Infections, Nontuberculous/metabolism ; Mycobacterium smegmatis/genetics ; Mycobacterium smegmatis/immunology ; Phenotype ; Signal Transduction ; THP-1 Cells
Czasopismo naukowe
Tytuł :
Laboratory biomarkers and prognosis in Covid-19, where do we stand?
Autorzy :
Israni A; Imperial College School of Medicine, Faculty of Medicine, Imperial College London, London, UK.
Goulden CJ; Imperial College School of Medicine, Faculty of Medicine, Imperial College London, London, UK.
Harky A; Department of Cardiothoracic Surgery, Liverpool Heart and Chest Hospital, Liverpool, UK.; Institute of Integrative biology, Faculty of Health and Life Science, University of Liverpool, Liverpool, UK.
Pokaż więcej
Źródło :
Reviews in medical virology [Rev Med Virol] 2021 Nov; Vol. 31 (6), pp. e2296. Date of Electronic Publication: 2021 Sep 13.
Typ publikacji :
Editorial
MeSH Terms :
COVID-19/*diagnosis
Cytokine Release Syndrome/*diagnosis
Disseminated Intravascular Coagulation/*diagnosis
SARS-CoV-2/*pathogenicity
Aspartate Aminotransferases/blood ; Asymptomatic Diseases ; Biomarkers/blood ; C-Reactive Protein/metabolism ; COVID-19/drug therapy ; COVID-19/mortality ; COVID-19/pathology ; Creatine Kinase/blood ; Cytokine Release Syndrome/drug therapy ; Cytokine Release Syndrome/mortality ; Cytokine Release Syndrome/pathology ; Disseminated Intravascular Coagulation/drug therapy ; Disseminated Intravascular Coagulation/mortality ; Disseminated Intravascular Coagulation/pathology ; Fibrin Fibrinogen Degradation Products/metabolism ; Humans ; Interleukin-6/blood ; L-Lactate Dehydrogenase/blood ; Leukocytes/immunology ; Leukocytes/virology ; Lymphopenia/diagnosis ; Lymphopenia/pathology ; Lymphopenia/virology ; Prognosis ; Severity of Illness Index ; Survival Analysis ; Thrombocytopenia/diagnosis ; Thrombocytopenia/pathology ; Thrombocytopenia/virology
Opinia redakcyjna
Tytuł :
Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS-CoV-2.
Autorzy :
Petrak RM; Metro Infectious Disease Consultants, Burr Ridge, Illinois, USA.
Skorodin NC; Metro Infectious Disease Consultants, Burr Ridge, Illinois, USA.
Van Hise NW; Metro Infectious Disease Consultants, Burr Ridge, Illinois, USA.
Fliegelman RM; Metro Infectious Disease Consultants, Burr Ridge, Illinois, USA.
Pinsky J; Metro Infectious Disease Consultants, Naperville, Illinois, USA.
Didwania V; Metro Infectious Disease Consultants, Elmhurst, Illinois, USA.
Anderson M; Metro Infectious Disease Consultants, Kankakee, Illinois, USA.
Diaz M; Metro Infectious Disease Consultants, Atlanta, Georgia, USA.
Shah K; Metro Infectious Disease Consultants, Atlanta, Georgia, USA.
Chundi VV; Metro Infectious Disease Consultants, Chicago, Illinois, USA.
Hines DW; Metro Infectious Disease Consultants, Chicago, Illinois, USA.
Harting BP; Metro Infectious Disease Consultants, Downers Grove, Illinois, USA.
Sidwha K; Metro Infectious Disease Consultants, Chicago, Illinois, USA.
Yu B; Metro Infectious Disease Consultants, Chicago, Illinois, USA.
Brune P; Metro Infectious Disease Consultants, Kansas City, Missouri, USA.
Owaisi A; Metro Infectious Disease Consultants, Bolingbrook, Illinois, USA.
Beezhold D; Metro Infectious Disease Consultants, Elmhurst, Illinois, USA.
Kent J; Metro Infectious Disease Consultants, Oak Lawn, Illinois, USA.
Vais D; Metro Infectious Disease Consultants, Chicago, Illinois, USA.
Han A; Metro Infectious Disease Consultants, Chicago, Illinois, USA.
Gowda N; Metro Infectious Disease Consultants, Troy, Michigan, USA.
Sahgal N; Metro Infectious Disease Consultants, Hinsdale, Illinois, USA.
Silverman J; Metro Infectious Disease Consultants, Royal Oak, Michigan, USA.
Stake J; Metro Infectious Disease Consultants, Waukegan, Illinois, USA.
Nepomuceno J; Metro Infectious Disease Consultants, McHenry, Illinois, USA.
Heddurshetti R; Metro Infectious Disease Consultants, Detroit, Michigan, USA.
Pokaż więcej
Źródło :
Clinical and translational science [Clin Transl Sci] 2021 Nov; Vol. 14 (6), pp. 2146-2151. Date of Electronic Publication: 2021 Oct 27.
Typ publikacji :
Journal Article; Multicenter Study
MeSH Terms :
Antibodies, Monoclonal, Humanized/*therapeutic use
COVID-19/*drug therapy
COVID-19/*therapy
Cytokine Release Syndrome/*therapy
Respiration, Artificial/*statistics & numerical data
COVID-19/immunology ; COVID-19/mortality ; COVID-19/virology ; Critical Illness/mortality ; Critical Illness/therapy ; Cytokine Release Syndrome/immunology ; Cytokine Release Syndrome/mortality ; Cytokine Release Syndrome/virology ; Female ; Hospital Mortality ; Humans ; Male ; Middle Aged ; Retrospective Studies ; SARS-CoV-2/immunology ; Severity of Illness Index ; Time Factors ; Time-to-Treatment ; Treatment Outcome
SCR Protocol :
COVID-19 drug treatment
Czasopismo naukowe
Tytuł :
C-reactive protein as an effector molecule in Covid-19 pathogenesis.
Autorzy :
Mosquera-Sulbaran JA; Instituto de Investigaciones Clinicas 'Dr. Americo Negrette', Facultad de Medicina, Universidad del Zulia, Maracaibo, Venezuela.
Pedreañez A; Catedra de Inmunologia, Escuela de Bioanalisis, Facultad de Medicina, Universidad del Zulia, Maracaibo, Venezuela.
Carrero Y; Facultad de Ciencias de la Salud, Carrera de Medicina, Universidad Tecnica de Ambato, Ambato, Ecuador.
Callejas D; Facultad de Ciencias de la Salud, Departamento de Ciencias Biologicas, Universidad Tecnica de Manabi, Portoviejo, Ecuador.
Pokaż więcej
Źródło :
Reviews in medical virology [Rev Med Virol] 2021 Nov; Vol. 31 (6), pp. e2221. Date of Electronic Publication: 2021 Feb 17.
Typ publikacji :
Journal Article; Systematic Review
MeSH Terms :
Anti-Inflammatory Agents/*therapeutic use
C-Reactive Protein/*antagonists & inhibitors
COVID-19/*drug therapy
Complement System Proteins/*immunology
Cytokine Release Syndrome/*drug therapy
SARS-CoV-2/*pathogenicity
ADAM17 Protein/antagonists & inhibitors ; ADAM17 Protein/genetics ; ADAM17 Protein/immunology ; Angiotensin-Converting Enzyme 2/antagonists & inhibitors ; Angiotensin-Converting Enzyme 2/genetics ; Angiotensin-Converting Enzyme 2/immunology ; Biomarkers/blood ; C-Reactive Protein/genetics ; C-Reactive Protein/immunology ; COVID-19/immunology ; COVID-19/pathology ; COVID-19/virology ; Celecoxib/therapeutic use ; Complement System Proteins/genetics ; Cytokine Release Syndrome/immunology ; Cytokine Release Syndrome/pathology ; Cytokine Release Syndrome/virology ; Cytokines/antagonists & inhibitors ; Cytokines/genetics ; Cytokines/immunology ; Disease Progression ; Doxycycline/therapeutic use ; Gene Expression Regulation ; Humans ; Randomized Controlled Trials as Topic ; Severity of Illness Index ; Survival Analysis
Czasopismo naukowe
Tytuł :
Interindividual immunogenic variants: Susceptibility to coronavirus, respiratory syncytial virus and influenza virus.
Autorzy :
Darbeheshti F; Department of Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.; Medical Genetics Network (MeGeNe), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
Mahdiannasser M; Department of Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Uhal BD; Department of Physiology, Michigan State University, East Lansing, Michigan, USA.
Ogino S; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Cancer Immunology and Cancer Epidemiology Programs, Dana-Farber Harvard Cancer Center, Boston, Massachusetts, USA.
Gupta S; Division of Basic and Clinical Immunology, Department of Medicine, University of California, Irvine, California, USA.
Rezaei N; Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.; Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.; Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
Pokaż więcej
Źródło :
Reviews in medical virology [Rev Med Virol] 2021 Nov; Vol. 31 (6), pp. e2234. Date of Electronic Publication: 2021 Mar 16.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Genetic Predisposition to Disease*
COVID-19/*immunology
Cytokine Release Syndrome/*immunology
Influenza, Human/*immunology
Respiratory Syncytial Virus Infections/*immunology
Severe Acute Respiratory Syndrome/*immunology
Antiviral Agents/therapeutic use ; Biological Variation, Individual ; COVID-19/drug therapy ; COVID-19/genetics ; COVID-19/virology ; Cytokine Release Syndrome/drug therapy ; Cytokine Release Syndrome/genetics ; Cytokine Release Syndrome/virology ; Gene Expression ; Humans ; Immunity, Innate ; Immunologic Factors/therapeutic use ; Influenza, Human/drug therapy ; Influenza, Human/genetics ; Influenza, Human/virology ; Mannose-Binding Lectin/genetics ; Mannose-Binding Lectin/immunology ; Orthomyxoviridae/drug effects ; Orthomyxoviridae/immunology ; Respiratory Syncytial Virus Infections/drug therapy ; Respiratory Syncytial Virus Infections/genetics ; Respiratory Syncytial Virus Infections/virology ; Respiratory Syncytial Viruses/drug effects ; Respiratory Syncytial Viruses/immunology ; SARS Virus/drug effects ; SARS Virus/immunology ; SARS-CoV-2/classification ; SARS-CoV-2/drug effects ; SARS-CoV-2/immunology ; Severe Acute Respiratory Syndrome/drug therapy ; Severe Acute Respiratory Syndrome/genetics ; Severe Acute Respiratory Syndrome/virology ; Toll-Like Receptors/genetics ; Toll-Like Receptors/immunology
Czasopismo naukowe
Tytuł :
Neonatal MIS-C: Managing the Cytokine Storm.
Autorzy :
Saha S; Fortis Hospital, Anandapur, Kolkata, India .
Pal P; Fortis Hospital, Anandapur, Kolkata, India.
Mukherjee D; The Mission Hospital, Durgapur, India.
Pokaż więcej
Źródło :
Pediatrics [Pediatrics] 2021 Nov; Vol. 148 (5). Date of Electronic Publication: 2021 Aug 25.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Cytokine Release Syndrome*/diagnosis
Cytokine Release Syndrome*/therapy
Cytokine Release Syndrome*/virology
Systemic Inflammatory Response Syndrome*/complications
Systemic Inflammatory Response Syndrome*/diagnosis
Systemic Inflammatory Response Syndrome*/therapy
COVID-19/*complications
COVID-19/diagnosis ; COVID-19/therapy ; Female ; Humans ; Infant, Newborn
SCR Disease Name :
pediatric multisystem inflammatory disease, COVID-19 related
Czasopismo naukowe
Tytuł :
Immune Responses to the Novel Coronavirus-2: Friend or Foe?
Autorzy :
Mahmoodpoor A; Professor of Anesthesiology and Critical Care Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Nader ND; Professor of Anesthesiology and Surgery, University at Buffalo, Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, USA.
Pokaż więcej
Źródło :
Immunological investigations [Immunol Invest] 2021 Nov; Vol. 50 (8), pp. 949-951. Date of Electronic Publication: 2020 Jul 21.
Typ publikacji :
Letter
MeSH Terms :
Immunity*
COVID-19/*diagnosis
Cytokine Release Syndrome/*immunology
Respiratory Distress Syndrome/*immunology
SARS-CoV-2/*immunology
COVID-19/complications ; COVID-19/immunology ; COVID-19/virology ; Cytokine Release Syndrome/epidemiology ; Cytokine Release Syndrome/pathology ; Cytokine Release Syndrome/virology ; Humans ; Lung/immunology ; Lung/pathology ; Lung/virology ; Respiratory Distress Syndrome/epidemiology ; Respiratory Distress Syndrome/virology ; Respiratory Mucosa/immunology ; Respiratory Mucosa/pathology ; Respiratory Mucosa/virology ; Severity of Illness Index
Opinia redakcyjna
Tytuł :
Abnormal Transcript Levels of Cytokines Among Iranian COVID-19 Patients.
Autorzy :
Samsami M; Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Fatemi A; Men's Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Jalili Khoshnoud R; Functional Neurosurgery Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Kohansal K; School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Hussen BM; Department of Pharmacognosy, College of Pharmacy, Hawler Medical University, Kurdistan Region, Erbil, Iraq.
Soghala S; Department of Microbiology, Faculty of Biological Sciences, North Tehran Branch, Islamic Azad University, Tehran, Iran.
Taheri M; Skull Base Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.; Institute of Human Genetics, Jena University Hospital, Jena, Germany.
Ghafouri-Fard S; Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. .
Pokaż więcej
Źródło :
Journal of molecular neuroscience : MN [J Mol Neurosci] 2022 Jan; Vol. 72 (1), pp. 27-36. Date of Electronic Publication: 2021 Dec 02.
Typ publikacji :
Journal Article
MeSH Terms :
Pandemics*
COVID-19/*blood
Cytokine Release Syndrome/*blood
Cytokines/*genetics
RNA, Messenger/*blood
Adult ; Aged ; Aged, 80 and over ; Blood Sedimentation ; C-Reactive Protein/analysis ; COVID-19/complications ; COVID-19/epidemiology ; Case-Control Studies ; Critical Care ; Cytokine Release Syndrome/etiology ; Female ; Gene Expression Regulation ; Humans ; Iran/epidemiology ; Male ; Middle Aged ; RNA, Messenger/genetics ; Real-Time Polymerase Chain Reaction ; Sensitivity and Specificity ; Severity of Illness Index
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies